REG - Verici Dx PLC - Publication of Circular

Verici DxAnnouncement

26/01/2024 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240126:nRSZ1002Ba&default-theme=true

RNS Number : 1002B  Verici Dx PLC  26 January 2024

26 January 2024

Verici Dx plc

("Verici" or the "Company")

Publication of Circular

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that, further to the announcement made at 7.00
a.m. on 24 January 2024 (RNS Number 6987A), the Circular has been published
today. The Circular will be posted to Shareholders that have elected to
receive hard copies of Shareholder documentation today and will also be
available later today on the Company's website at
https://vericidx.com/investors/documents/
(https://vericidx.com/investors/documents/) .

Enquiries:

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via IR-Connect
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Sam Butcher / Jalini Kalaravy

 IR-Connect                                               www.ir-connect.co.uk
 Lorraine Rees                                            investors@vericidx.com

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici is a developer of a complementary suite of leading-edge tests forming a
kidney transplant platform for personalised patient and organ response risk to
assist clinicians in medical management for improved patient outcomes. The
underlying technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the immune
response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CIRBDGDBGXDDGSL